D
Denis M. Collins
Researcher at Dublin City University
Publications - 51
Citations - 915
Denis M. Collins is an academic researcher from Dublin City University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 14, co-authored 36 publications receiving 662 citations.
Papers
More filters
Journal ArticleDOI
Src: a potential target for the treatment of triple-negative breast cancer
D. Tryfonopoulos,Siun Walsh,Denis M. Collins,Louise Flanagan,Cecily Quinn,B. Corkery,Enda W. McDermott,Denis Evoy,Aisling Pierce,Norma O'Donovan,John Crown,Michael J. Duffy +11 more
TL;DR: It is concluded that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.
Journal ArticleDOI
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
Denis M. Collins,Norma O'Donovan,Patricia M. McGowan,Finbarr O'Sullivan,Michael J. Duffy,John Crown +5 more
TL;DR: The results suggest that Her-2-non-amplified breast cancer cells, with low but detectable levels of HER-2 protein, can bind trastuzumab and initiate ADCC.
Journal ArticleDOI
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
TL;DR: This review focuses on immune checkpoint inhibitors - immunomodulatory agents that aim to relieve tumour-mediated immune-cell suppression that have shown impressive results in a range of solid cancers, particularly melanoma and non-small cell lung cancer.
Journal ArticleDOI
Acquired Resistance to Antibody-Drug Conjugates
TL;DR: Preclinical and clinical findings are summarized that shed light on the mechanisms of acquired resistance to ADC therapies, which are tailored to the specific nature and interplay of the three ADC constituents: the antibody, the linker, and the payload.
Journal ArticleDOI
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Naomi Elster,Denis M. Collins,Sinead Toomey,John Crown,Alex J Eustace,Bryan T. Hennessy,Bryan T. Hennessy +6 more
TL;DR: With the rapidly expanding understanding of HER2 signalling mechanisms along with the repertoire of HER family and other targeted therapies, it is likely that the near future holds further dramatic improvements to the prognosis of women with HER2-positive BC.